ArticleTranslational oncology2018
CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.
Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.Bioscience reports · 2020Pooled it
- Identification of STEAP4, EPC1, and CLEC1B as non-invasive candidate biomarkers for hepatocellular carcinoma using integrated bioinformatics analysis.Biotechnology reports (Amsterdam, Netherlands) · 2026Article
- Integrated machine learning and multi-dataset analysis identify SDS as a diagnostic and immune-related hub gene in hepatoblastoma.Frontiers in oncology · 2026Article
- Differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma with MRI and tumor markers: a multi-center study.European radiology · 2026Article
- Decoding EGFR A289 Mutation in Glioblastoma: A Predictive Biomarker Framework and Targeted Therapeutic Insights.Journal of molecular neuroscience : MN · 2025Article
- Decreased plasma level of C-type lectin-like receptor 2 (CLEC-2) in patients with breast cancer.International journal of medical sciences · 2025Article
- Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate.Pathobiology : journal of immunopathology, molecular and cellular biology · 2025Article
- Synergistic upregulation of PD‑L1 in tumor cells and CD39 in tumor‑infiltrating CD8Oncology letters · 2024Article
- Construction and validation of a joint diagnosis model based on random forest and artificial intelligence network for hepatitis B-related hepatocellular carcinoma.Translational cancer research · 2024Article
- Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Macrophage Polarization-Related Genes.Journal of hepatocellular carcinoma · 2024Article
- Establishment and Validation of the LI-RADS Morphologic Type II Hepatocellular Carcinoma Early Recurrence Risk Scoring System.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Article
- Comprehensive analysis identifies CLEC1B as a potential prognostic biomarker in hepatocellular carcinoma.Cancer cell international · 2023Article
- Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma.Scientific reports · 2023Article
- Tumor-stroma ratio predicts prognosis and PD-L1 expression in hepatocellular carcinoma.BMC cancer · 2023Article
- Evaluation of Preoperative Microvascular Invasion in Hepatocellular Carcinoma Through Multidimensional Parameter Combination Modeling Based on Gd-EOB-DTPA MRI.Journal of clinical and translational hepatology · 2023Article
- Exploring the Expression and Prognosis of Mismatch Repair Proteins and PD-L1 in Colorectal Cancer in a Chinese Cohort.Cancer management and research · 2023Article
- A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.BMC cancer · 2022Article
- Dissecting novel mechanisms of hepatitis B virus related hepatocellular carcinoma using meta-analysis of public data.World journal of gastrointestinal oncology · 2022Article
- Curcumin-Based Inhibitors of Thrombosis and Cancer Metastasis Promoting Factor CLEC 2 from Traditional Medicinal SpeciesEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis.European radiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous tumor hemorrhage (TH) is frequently observed in solid tumors including human hepatocellular carcinoma (HCC). TH implies fast-growing and worse tumor immunological microenvironment; however, the underlying mechanism remains largely unknown. CLEC1B is a signature gene highly associated with tumor progression. PD-L1 expression is a key biomarker predictive of immune checkpoint therapies, which showed astonishing effect on various types of tumor. We assume that, in HCC, TH may closely associate with the expression of these two molecules. In this study, 136 patients with HCC were enrolled. qRT-PCR showed that CLEC1B expression is significantly lower in HCC tumor tissue. Immunohistochemistry of HCC tissue microarrays demonstrated that PD-L1
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.